Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesamorelin for Cognition in Aging HIV-Infected Persons
NCT02572323Phase 2Completed
- Sponsor
- University of California, San Diego
- Start
- Feb 2017
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tesamorelin in Mild Cognitive Impairment (MCI) (2 arms), sponsored by University of California, San Diego. Primary endpoint: Change in Neurocognitive Performance at 24 weeks. Started Feb 2017; status: completed.
02
Drugs
tesamorelin
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02572323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572323.